Harry is a PhD candidate at the School of Pharmacy, The University of Sydney, and a registered pharmacist. His research aims to improve and personalise medication use in people living with dementia through advanced pharmacoepidemiological approaches. He has experience working with diverse data sources, including randomised controlled trial datasets, medication dispensing claims, and hospital administrative records. His current work focuses on better understanding and individualising antipsychotic prescribing in dementia, to support safer and more evidence-informed clinical decision-making.

Gesnita Nugraheni PhD Candidate, Sydney School of Pharmacy | Lecturer, Universitas Airlangga, Indonesia I am passionate about improving medication management and safety for older adults. My research focuses on optimizing medication systems and reducing risks associated with inappropriate prescribing. Currently, I am investigating the use of psychotropic medicines in Australian residential aged care homes—examining prescribing trends, review practices, and their outcomes. I am also interested in strengthening medication management systems in aged care in low- and middle-income countries, particularly Indonesia, to enhance quality and safety. I welcome opportunities for research collaboration in these areas.

Qingke (Demi) He is a pharmacist and PhD candidate at Monash University’s Centre of Medication Use and Safety. Her research uses pharmacoepidemiology to evaluate trends and outcomes of glucose-lowering drug use in Alzheimer’s and Parkinson’s disease, translating real-world data into clinical insights for safer prescribing and repurposing.

Dr. Basavaraj Poojar is a clinical pharmacologist and public health researcher with a PhD in Clinical Pharmacology. His work focuses on pharmacoepidemiology, pharmacovigilance, medication safety, and real-world evidence to inform policy and practice, particularly in resource-limited settings. He has led national-level research, including a spatiotemporal analysis of drug-resistant tuberculosis for India’s National TB Elimination Program, and has co-investigated an ICMR-funded study on occupational ionizing radiation exposure using a One Health approach. Dr. Poojar is a member of the WHO Global Research Agenda on Knowledge Translation Committee and an active Cochrane member, contributing to evidence synthesis through Cochrane Crowd. He has authored multiple book chapters, reviewed for peer-reviewed journals, and is committed to capacity building through mentoring and medical education.

I am an Associate Professor of Medical Pharmacology at the University of Health Sciences, Istanbul, Türkiye. I hold an MD and completed my residency in Medical Pharmacology at Marmara University, followed by a PhD in Neuroscience at Acibadem University. My diverse research background includes a visiting fellowship at Lund University’s B.R.A.I.N.S. Institute in Sweden. My work spans neuropharmacology, specifically epilepsy mechanisms, and clinical toxicology, with a focus on drug safety and teratology. Recently, I have expanded my research into digital health, critically evaluating the reliability and safety of Artificial Intelligence in pharmacology. I serve as a Working Group Leader in European COST Actions and is an active member of the Turkish Pharmacological Society.

Nihal Kayır is a PhD candidate in Medical Pharmacology at Istanbul Medipol University Faculty of Medicine. She is currently working in the Oncology Polyclinic and Chemotherapy Unit at different Hospital, where she is actively involved in clinical oncology practice, cancer researches and pharmacotherapy management. Kayir serves as the Türkiye Representative Delegate of the European Society of Oncology Pharmacy (ESOP) and is a member of the Turkish Pharmacology Association (TFD), the British Pharmacological Society (BPS), and the American Society for Pharmacology and Experimental Therapeutics (ASPET). Her research interests focus on oncology pharmacology, pharmacoeconomics, and translational pharmacological research.She has presented several oral and poster presentations at international pharmacology and medical congresses and is involved in EU-supported projects, including the Stronger Together Against Cancer (STAC) initiative. In addition, she participates actively in international scientific meetings, innovation events, and oncology-focused training programs, reflecting her strong engagement in interdisciplinary research and clinical pharmacology. She currently works as a pharmacologist at Ankara Oncology Hospital, which is the first and only one of its kind in Türkiye.